Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Progress in the discovery and development of anticancer agents from marine cyanobacteria
Hendrik Luesch*ab,
Emma K. Ellisa,
Qi-Yin Chena and
Ranjala Ratnayakea
aDepartment of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, 1345 Center Drive, Gainesville, Florida 32610, USA. E-mail: luesch@cop.ufl.edu
bProgram in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, 169857, Singapore
First published on 9th February 2026
Abstract
Correction for ‘Progress in the discovery and development of anticancer agents from marine cyanobacteria’ by Hendrik Luesch et al., Nat. Prod. Rep., 2025, 42, 208–256, https://doi.org/10.1039/D4NP00019F.
The authors regret that are errors in the structures shown in Fig. 2 and Fig. 4 of the published article. The changes made and the corrected figures can be found here.
In Fig. 2 the MMAF-based ADC is now depicted separately from MMAE-based ADCs because the linker is shorter compared with MMAE-based ADCs. The caption for Fig. 2 as included in the original article and here was correct at the time of publication. However, the authors would like to note that the MMAF-based ADC (Blenrep) has since been approved for clinical use.
In Fig. 4 the propyl carbon chain between dolastatin 15 and the maleimido group of compound 27a has been updated to an ethyl carbon chain.
 | ||
| Fig. 2 Structures of dolastatin 10 (1a), and the synthetic analogues of monomethyl auristatins developed as ADCs approved by FDA for clinical use. The MMAF-based ADC has been withdrawn. | ||
 | ||
| Fig. 4 Dolastatin 15 (26a) and clinically evaluated analogues, including relevant ADCs that advanced to clinical trials. | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2026 |